logo-loader
viewImmuPharma PLC

ImmuPharma chairman 'delighted' with £4.1mln fund raise support

Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM) talks to Proactive about the company's £4.1mln raise from investors after an oversubscribed placing.

The new cash infusion is to be used to strengthen its balance sheet as negotiations take place with potential commercial partners for its flagship drug, Lupuzor.

Quick facts: ImmuPharma PLC

Price: 17.734 GBX

AIM:IMM
Market: AIM
Market Cap: £29.68 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ImmuPharma: Analyst discusses 'impressive and potentially blockbuster' ...

The Life Sciences Division's Navid Malik gives his view on the recent recent deal ImmuPharma PLC (LON:IMM) struck with US speciality drugs group Avion Pharmaceuticals. Malik reckons its lupus candidate Lupuzor could become a 'US blockbuster' by generating over US$1bn revenues per year.

3 hours, 1 minute ago

2 min read